Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: High number of uncaptured cases by cancer registries

Blood

Volumn 117, Issue 26, 2011, Pages 7121-7125

  Cogle, Christopher R ^a   Craig, Benjamin M ^b   Rollison, Dana E ^b   List, Alan F ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALGORITHM; ARTICLE; BILLING AND CLAIMS; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEALTH SURVEY; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEDICARE; MYELODYSPLASTIC SYNDROME; MYELODYSPLASTIC SYNDROME WITH 5Q DELETION SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SENSITIVITY AND SPECIFICITY; THERAPY RELATED MYELODYSPLASTIC SYNDROME; VALIDITY;

EID: 79959851207     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-337964     Document Type: Article

References (20)

1. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: Results from regional cancer surveys and hospitalbased statistics. Int J Hematol. 2001;73(4):405-410. (Pubitemid 33758872)
2. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
3. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52.
4. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-1542. (Pubitemid 46595689)
5. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542-1551.
6. Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma. Cancer. 2010;116(22):5279-5289.
7. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196-205.
8. Ma X, Wang R. Ascertainment of patients with myelodysplastic syndromes. J Clin Oncol. 2011; 29(1):e16; author reply e17.
9. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-18.
10. The Henry J. Kaiser Family Foundation. Medicare Advantage Fact Sheet April 2003. www.kff.org/ medicare/upload/Medicare-Advantage-Fact-Sheet.pdf. Accessed May 17, 2011.
11. The Henry J. Kaiser Family Foundation. Medicare Advantage Fact Sheet April 2004. www.kff.org/ medicare/upload/Medicare-Advantage-Fact-Sheet.pdf. Accessed. May 17, 2011.
12. The Henry J. Kaiser Family Foundation. Medicare Advantage Fact Sheet. September 2005. www. kff.org/medicare/upload/Medicare-Advantage- Fact-Sheet.pdf Accessed May 17, 2011.
13. Johnson C, Adamo M, Peace S, Percy-Laurry A, editors. Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual. Version 16. Bethesda, MD: National Cancer Institute; 2010:119.
14. De Roos AJ, Deeg HJ, Onstad L, et al. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol. 2010;85(10):765-770.
15. Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005;19(6):301-319. (Pubitemid 41571931)
16. Gologan R, Georgescu D, Tatic A, Radulescu I, Vasilache D. Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania. Leuk Res. 2009;33(11):1556-1561.
17. National Comprehensive Cancer Network. NCCN Guidelines & Clinical Resources: Myelodysplastic syndromes. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp. Accessed May 17, 2011.
18. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
19. Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116(9):2174-2179.
20. American Society of Hematology. Changes impacting hematology ICD-9 codes become effective October 1. 2009. http://www.hematology.org/ News/2009/4282.aspx. Accessed May 17, 2011.